SOD1 and amyotrophic lateral sclerosis: Recently, an anti-sense oligonucleotide therapeutic, Tofersen, targeting SOD1 received FDA accelerated approval based on the ability of the drug to lower blood NfL levels in patients with SOD1 mutation-mediated ALS in combination with signs of clinical benefit [18].